Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $21.00 price objective on the biotechnology company's stock.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird cut their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, November 26th. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Trading Down 5.4 %

ENTA stock traded down $0.41 on Tuesday, hitting $7.09. 317,292 shares of the company's stock traded hands, compared to its average volume of 561,088. Enanta Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $17.80. The stock has a market cap of $151.34 million, a price-to-earnings ratio of -1.30 and a beta of 0.54. The stock has a fifty day moving average of $5.74 and a 200-day moving average of $9.50.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. On average, equities research analysts anticipate that Enanta Pharmaceuticals will post -5.05 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jay R. Luly acquired 45,000 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were purchased at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the purchase, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 13.89% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENTA. US Bancorp DE increased its stake in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after buying an additional 4,243 shares during the period. Quest Partners LLC increased its stake in Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company's stock valued at $198,000 after buying an additional 7,535 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth $122,000. Valence8 US LP acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth $207,000. Finally, FMR LLC increased its stake in shares of Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company's stock worth $511,000 after purchasing an additional 7,839 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.